Date: 2016-02-08
Type of information: Nomination
Compound:
Company: Intarcia Therapeutics (USA - CA)
Therapeutic area: Metabolic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On February 8, 2016, Intarcia Therapeutics announced the appointment of John Yee, MD, MPH, into the newly created role of Vice President, Head of Global Medical Affairs, Safety and Operations. Dr. Yee has two decades of leadership experience at leading pharmaceutical, biotechnology, and health care companies, and at a major academic medical center. Most recently Dr. Yee served as VP, Head of Medical Affairs, US Diabetes, and VP, US Head Medical Officer at AstraZeneca, where he led medical affairs across all therapeutic areas, and led the medical launch of multiple cardiovascular and metabolic products, including: Bydureon® (exenatide extended release) for injectable suspension, Farxiga® (dapagliflozin), Xigduo™ XR (dapagliflozin and metformin HCI extended release tablets), Myalept® (metreleptin) for injection, and Brilinta® (ticagrelor tablets). In his new role at Intarcia, Dr. Yee will be a member of the Leadership Team and an Executive Officer of the Company, and he will report directly to Kurt Graves, Chairman, President and CEO.
Intarcia Therapeutics aims to file its first NDA in 2016 and prepares for the launch of ITCA 650 in the second half of 2017.
Financial terms:
Latest news:
